Skip to content
CLIC-VA Logo
  • Home
  • Legislation Center
  • Subscribe
  • About
  • Login

HB 2233 Prescription drug price transparency; manufacturer reporting requirements. Introduced by: Mark D. Sickles

Home/Health Care/Rx/HB 2233 Prescription drug price transparency; manufacturer reporting requirements. Introduced by: Mark D. Sickles
Previous Next

HB 2233 Prescription drug price transparency; manufacturer reporting requirements. Introduced by: Mark D. Sickles

By Carol Stopps|2023-01-19T11:29:46-05:00January 19th, 2023|Rx|Comments Off on HB 2233 Prescription drug price transparency; manufacturer reporting requirements. Introduced by: Mark D. Sickles

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: Carol Stopps

Related Posts

  • HB 2274 Pharmacist scope of practice; initiation of treatment for various diseases and conditions. Introduced by: Terry G. Kilgore

    HB 2274 Pharmacist scope of practice; initiation of treatment for various diseases and conditions. Introduced by: Terry G. Kilgore

  • HB 1787 Prescription for controlled substance; practitioner-patient relationship.

    HB 1787 Prescription for controlled substance; practitioner-patient relationship.

  • SB 957 Prescription Drug Affordability Board and Fund established; drug cost affordability review.

    SB 957 Prescription Drug Affordability Board and Fund established; drug cost affordability review.

  • SB 894 Drug Control Act; adds certain chemicals to Schedule I.

    SB 894 Drug Control Act; adds certain chemicals to Schedule I.

Page load link